Clinical experience with etanercept in the treatment of psoriasis;Etanercept en la psoriasis. Experiencia clínica

Actas Dermo-Sifiliograficas

Volumn 99, Issue 7, 2008, Pages 540-545

  Martín González, Blanca ^a   Sanchez Carazo J L ^a   Perez Ferriols A ^a   Laguna, C ^a   Oliver, V ^a   Alegre, V ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Biologic therapy; Etanercept; Psoriasis; Systemic therapy

Indexed keywords

ETANERCEPT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; OBSERVATIONAL STUDY; PATIENT MONITORING; PSORIASIS; PSORIASIS AREA SEVERITY INDEX; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 51849123825     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(08)74739-2     Document Type: Article

References (13)

1. Krueger G, Koo J, Lebwohl L, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
2. Ferrándiz C, Bordas X, García-Patos V, Puig S, Pujol R, Smandía A, et al. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol. 2001;15: 20-3.
3. Finlay AY, Coles, BC. The effects of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236-44.
4. Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies. US experiences. Br J Dermatol. 2004;151:3-15.
5. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153:486-97.
6. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49: S44-50.
7. López Estebaranz JL. Etanercept. Estructura química, farmacocinética y mecanismo de acción. Actas Dermosifiliogr. 2005;96 Supl 3:2-9.
8. Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M, et al. Correlated increases of tumor necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriasic patients: relationships with disease severity. Clin Exp Dermatol. 1994;19:383-7.
9. Herrera Ceballos E, Habicheyn S. Eficacia clínica del etanercept en psoriais y artritis psoriásica. Actas Dermosifiliogr. 2005;96 Supl 3:10-24.
10. García-Patos Briones V. Seguridad de etanercept. Actas Dermosifiliogr. 2005;96:S25-32.
11. Mahiques Santos L, Martínez Menchón T, Sánchez Carazo JL, Pérez-Ferriols A, Soriano Navarro CJ, Fortea Baixauli JM, et al. Tratamiento de la psoriasis refractaria con etanercept. Med Clin (Barc). 2005;125:371-3.
12. Gamo R, López-Estebaranz JL. Terapia biológica y psoriasis. Actas Dermosifiliogr. 2006;97:1-17.
13. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicentric active-surveillance report. Arthritis Rheum. 2003;48:2122-7.